The Interplay of Tumor Vessels and Immune Cells Affects Immunotherapy of Glioblastoma
Biomedicines, 2022 Immunotherapies with immune checkpoint inhibitors or adoptive cell transfer have become powerful tools to treat cancer. These treatments act via overcoming or alleviating tumor-induced immunosuppression, thereby enabling effective tumor clearance ...
Mitrajit Ghosh +2 more
doaj +1 more source
Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001. [PDF]
, 2016 Neuroendocrine tumors (NETs) are grouped together as a single class on the basis of histologic appearance, immunoreactivity for the neuroendocrine markers chromogranin A and synaptophysin, and potential secretion of hormones, neurotransmitters ...
Brzezniak, Christina +11 more
core +4 more sources
Multi-Omics Profiling of the Tumor Microenvironment: Paving the Way to Precision Immuno-Oncology
Frontiers in Oncology, 2018 The tumor microenvironment (TME) is a multifaceted ecosystem characterized by profound cellular heterogeneity, dynamicity, and complex intercellular cross-talk.
Francesca Finotello, Federica Eduati
doaj +1 more source
npj Precision Oncology, 2021 A single dose of bevacizumab reduced the density of angiopoietin-2-positive vessels while improving the infiltration of CD4+ T and CD8+ T cells, and mature dendritic cells in patients with primary triple-negative breast cancer.
Yves Boucher +10 more
doaj +1 more source
Immune checkpoint: The novel target for antitumor therapy
Genes and Diseases, 2021 Inhibitory checkpoint molecules include programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1), cytotoxic T lymphocyte antigen-4 (CTLA-4), human endogenous retrovirus-H Long terminal repeat-associating 2 (HHLA2), B7 homolog 4 protein (B7 ...
Xianghu Jiang +3 more
doaj +1 more source
TAM receptor tyrosine kinases in cancer drug resistance [PDF]
, 2017 Receptor tyrosine kinases (RTK) are major regulators of key biological processes, including cell growth, survival, and differentiation, and were established early on as proto-oncogenes, with aberrant expression linked to tumor progression in many cancers.
Hafizi, Sassan, Vouri, Mikaella
core +1 more source
Oncologic Emergencies: Immune-Based Cancer Therapies and Complications [PDF]
, 2020 Cancer therapies have undergone several recent advancements. Current cancer treatments include immune-based therapies comprised of checkpoint inhibitors, and adoptive immunotherapy; each treatment has the potential for complications that differ from ...
Brém, Elizabeth +2 more
core
CD8+T cell responsiveness to anti-PD-1 is epigenetically regulated by Suv39h1 in melanomas
Nature Communications, 2022 Tumor-infiltrating CD8 + T cells progressively lose functionality and fail to reject tumors. The underlying mechanism and re-programing induced by checkpoint blockers are incompletely understood.
Leticia Laura Niborski +23 more
doaj +1 more source
Trial watch: Toll-like receptor ligands in cancer therapy
OncoImmunology, 2023 Accumulating evidence indicates that Toll-like receptor (TLR) agonists proficiently (re)instore cancer immunosurveillance as immunological adjuvants. So far, three TLR agonists have been approved by regulatory agencies for use in oncological applications.
Julie Le Naour, Guido Kroemer
doaj +1 more source
Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology
Molecules, 2019 Cancer cells can evade immune surveillance through the molecular interactions of immune checkpoint proteins, including programmed death 1 (PD-1), PD-L1, and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). Since 2011, the FDA-approved antibody drugs
Hyun Tae Lee +2 more
doaj +1 more source